Related coverage linked through entity extraction aliases.
Jun 21, 2026
In Australia, 19 women are diagnosed daily with gynaecological cancer, and experts say late detection is the primary issue. Ovarian cancer is often caught at advanced stages, while endometrial cancer deaths are rising. Personal stories underscore the need for early symptom awareness.
Jun 16, 2026
Sensei Biotherapeutics has changed its name to Faeth Therapeutics following its February 2026 acquisition of the biotechnology company. The name change accompanies a $200 million private placement financing to advance PIKTOR, an investigational all-oral multi-node inhibitor targeting the PI3K/AKT/mTOR pathway in endometrial and breast cancer. Topline Phase 2 data in endometrial cancer is anticipated in the second half of 2026.
Jun 03, 2026
GLP-1 receptor agonists combined with progestin therapy significantly reduce endometrial cancer risk in women with uterine hyperplasia, according to a JAMA Network Open study. A separate meta-analysis finds patients regain 60% of weight lost one year after stopping GLP-1 RAs, with weight regain plateauing at 75.3% of treatment loss.
May 30, 2026
Tempus has launched "Preview," an AI-powered tool that provides early cancer insights within one day of sample receipt to inform treatment planning. The tool focuses on high-impact biomarkers including MSI-H, EGFR mutations, and FGFR fusions across several cancer types. The launch aligns with expert emphasis on the critical role of early biomarker testing in personalizing therapy for EGFR-mutated NSCLC.
May 22, 2026
A phase II trial of TAK-007 CAR-NK therapy in R/R B-cell NHL showed a 60.9% overall response rate. Preclinical CAR-NKT therapy eliminated endometrial tumors in models. Optimized costimulatory domains (2B4-DAP12) boosted CAR-NK tumor killing.
May 21, 2026
Acrivon Therapeutics said its wholly owned laboratory in Watertown received Massachusetts CLIA certification with a full license to conduct patient testing and develop companion diagnostics. The company said the lab is expected to be fully operational in the first half of 2026 and will support targeted therapeutics development.
May 19, 2026
MSD said sacituzumab tirumotecan improved overall survival and progression-free survival in the Phase III TroFuse-005 trial in endometrial cancer. The study also met its objective response rate endpoint.
May 07, 2026
Sensei Biotherapeutics dosed the first patient in a Phase 1b/2 trial of PIKTOR (sapanisertib + serabelisib) in HR+/HER2- advanced breast cancer. The multi-node PI3K/AKT/mTOR inhibitor previously showed a 47% overall response rate in a Phase 1b trial.
Mar 05, 2026
New research reveals GLP-1 receptor agonists reduce substance use disorders by 14%, lower Parkinson's disease risk after 5-10 years of use, and cut endometrial cancer risk by 66% when combined with progestin therapy.
Feb 27, 2026
New research shows cancer survivors who exercise reduce their risk of cancer-related death, while expert panel recommends exercise as essential for older cancer patients during and after treatment.
Feb 19, 2026
A comprehensive market report reveals over 180 companies are developing more than 200 PD-1 and PD-L1 inhibitor drugs, with recent fast-track designations and successful Phase III trial results driving expansion in cancer immunotherapy.
Feb 13, 2026
The FDA has approved labeling changes to six menopausal hormone therapy products, removing boxed warnings related to cardiovascular disease, breast cancer, and probable dementia that had been in place since 2003.
